Overall survival results from the randomized phase 2 study of palbociclib in combination with letrozole versus letrozole alone for first-line treatment of ER+/HER2− advanced breast cancer (PALOMA-1, TRIO-18)

User: Guest

Title:: Overall survival results from the randomized phase 2 study of palbociclib in combination with letrozole versus letrozole alone for first-line treatment of ER+/HER2− advanced breast cancer (PALOMA-1, TRIO-18)
Document type:: Zeitschriftenaufsatz
Author(s):: Finn, Richard S.; Boer, Katalin; Bondarenko, Igor; Patel, Ravindranath; Pinter, Tamas; Schmidt, Marcus; Shparyk, Yaroslav V.; Thummala, Anu; Voitko, Nataliia; Bananis, Eustratios; McRoy, Lynn; Wilner, Keith; Huang, Xin; Kim, Sindy; Slamon, Dennis J.; Ettl, Johannes
Journal title:: Breast Cancer Research and Treatment
Year:: 2020
Journal volume:: 183
Journal issue:: 2
Pages contribution:: 419-428
Fulltext / DOI:: doi:10.1007/s10549-020-05755-7
Publisher:: Springer Science and Business Media LLC
E-ISSN:: 0167-68061573-7217
Date of publication:: 18.07.2020
BibTeX

Occurrences: